Regeneron Pharmaceuticals Statistics
Total Valuation
REGN has a market cap or net worth of $51.81 billion. The enterprise value is $36.88 billion.
| Market Cap | 51.81B |
| Enterprise Value | 36.88B |
Important Dates
The last earnings date was Tuesday, April 29, 2025, before market open.
| Earnings Date | Apr 29, 2025 |
| Ex-Dividend Date | May 20, 2025 |
Share Statistics
REGN has 105.67 million shares outstanding. The number of shares has increased by 0.13% in one year.
| Current Share Class | 103.85M |
| Shares Outstanding | 105.67M |
| Shares Change (YoY) | +0.13% |
| Shares Change (QoQ) | -2.28% |
| Owned by Insiders (%) | 5.44% |
| Owned by Institutions (%) | 90.19% |
| Float | 99.75M |
Valuation Ratios
The trailing PE ratio is 12.43 and the forward PE ratio is 13.60. REGN's PEG ratio is 2.15.
| PE Ratio | 12.43 |
| Forward PE | 13.60 |
| PS Ratio | 3.75 |
| Forward PS | 3.47 |
| PB Ratio | 1.77 |
| P/TBV Ratio | 1.84 |
| P/FCF Ratio | 16.70 |
| P/OCF Ratio | 13.11 |
| PEG Ratio | 2.15 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.25, with an EV/FCF ratio of 11.89.
| EV / Earnings | 8.20 |
| EV / Sales | 2.62 |
| EV / EBITDA | 8.25 |
| EV / EBIT | 9.28 |
| EV / FCF | 11.89 |
Financial Position
The company has a current ratio of 4.93, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.93 |
| Quick Ratio | 3.90 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.60 |
| Debt / FCF | 0.87 |
| Interest Coverage | 83.17 |
Financial Efficiency
Return on equity (ROE) is 15.96% and return on invested capital (ROIC) is 8.04%.
| Return on Equity (ROE) | 15.96% |
| Return on Assets (ROA) | 6.91% |
| Return on Invested Capital (ROIC) | 8.04% |
| Return on Capital Employed (ROCE) | 11.70% |
| Revenue Per Employee | $932,457 |
| Profits Per Employee | $297,849 |
| Employee Count | 15,106 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 2.44 |
Taxes
In the past 12 months, REGN has paid $484.90 million in taxes.
| Income Tax | 484.90M |
| Effective Tax Rate | 9.73% |
Stock Price Statistics
The stock price has decreased by -49.27% in the last 52 weeks. The beta is 0.43, so REGN's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | -49.27% |
| 50-Day Moving Average | 590.82 |
| 200-Day Moving Average | 791.80 |
| Relative Strength Index (RSI) | 32.32 |
| Average Volume (20 Days) | 1,493,464 |
Short Selling Information
The latest short interest is 2.80 million, so 2.65% of the outstanding shares have been sold short.
| Short Interest | 2.80M |
| Short Previous Month | 2.89M |
| Short % of Shares Out | 2.65% |
| Short % of Float | 2.81% |
| Short Ratio (days to cover) | 2.07 |
Income Statement
In the last 12 months, REGN had revenue of $14.09 billion and earned $4.50 billion in profits. Earnings per share was $39.43.
| Revenue | 14.09B |
| Gross Profit | 6.87B |
| Operating Income | 3.98B |
| Pretax Income | 4.78B |
| Net Income | 4.50B |
| EBITDA | 4.47B |
| EBIT | 3.98B |
| Earnings Per Share (EPS) | $39.43 |
Balance Sheet
The company has $8.35 billion in cash and $2.70 billion in debt, giving a net cash position of $14.92 billion or $141.21 per share.
| Cash & Cash Equivalents | 8.35B |
| Total Debt | 2.70B |
| Net Cash | 14.92B |
| Net Cash Per Share | $141.21 |
| Equity (Book Value) | 29.39B |
| Book Value Per Share | 277.50 |
| Working Capital | 14.01B |
Cash Flow
In the last 12 months, operating cash flow was $3.95 billion and capital expenditures -$851.30 million, giving a free cash flow of $3.10 billion.
| Operating Cash Flow | 3.95B |
| Capital Expenditures | -851.30M |
| Free Cash Flow | 3.10B |
| FCF Per Share | $29.35 |
Margins
Gross margin is 48.80%, with operating and profit margins of 28.22% and 31.94%.
| Gross Margin | 48.80% |
| Operating Margin | 28.22% |
| Pretax Margin | 35.38% |
| Profit Margin | 31.94% |
| EBITDA Margin | 31.74% |
| EBIT Margin | 28.22% |
| FCF Margin | 22.02% |
Dividends & Yields
This stock pays an annual dividend of $1.76, which amounts to a dividend yield of 0.36%.
| Dividend Per Share | $1.76 |
| Dividend Yield | 0.36% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 4.46% |
| Buyback Yield | -0.13% |
| Shareholder Yield | 0.23% |
| Earnings Yield | 8.68% |
| FCF Yield | 5.99% |
Analyst Forecast
The average price target for REGN is $891.17, which is 81.77% higher than the current price. The consensus rating is "Buy".
| Price Target | $891.17 |
| Price Target Difference | 81.77% |
| Analyst Consensus | Buy |
| Analyst Count | 23 |
| Revenue Growth Forecast (5Y) | 7.22% |
| EPS Growth Forecast (5Y) | 13.58% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGN has an Altman Z-Score of 9.55 and a Piotroski F-Score of 3.
| Altman Z-Score | 9.55 |
| Piotroski F-Score | 3 |